Results 181 to 190 of about 237,979 (279)

A comprehensive analysis of digital health-focused Living Labs: innovative approaches to dementia. [PDF]

Front Med (Lausanne)
Figueiredo T, Midão L, Carrilho J, Videira Henriques D, Alves S, Duarte N, Bessa MJ, Fidalgo JM, García M, Facal D, Felpete A, Filgueira IR, Carlos Bernárdez J, Rodríguez M, Costa E.   +14 more
europepmc   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Living labs opened dialogues about antibiotic use in dairy cattle and pig sectors - Insights from a Danish case study based on participatory action research. [PDF]

Acta Vet Scand
Vaarst M, Studnitz M, Krogh MA, Kongsted H.   +3 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Transforming European Food Systems with multi-actor networks and Living Labs through the FoodSHIFT Approach. [PDF]

Open Res Eur
Schafer LJ, Anthouli A, Schmidt A, Beblek A, Fruehbeisser A, Walthall B, Mingolla C, Rogozan C, Petruzzella D, Wascher D, Volpe F, Ruggeri G, Arciniegas G, Vicente-Vicente JL, Riviou K, Valta K, Marijke Wenzel L, Labellarte L, Crivits M, Swiader M, Lysak M, Sylla M, Eyre P, Barbu R, Corsi S, Henriksen CB.   +25 more
europepmc   +1 more source

Living Labs as open innovation systems for knowledge exchange: solutions for sustainable innovation development [PDF]

, 2016
Baccarne, Bastiaan, Ballon, Pieter, De Marez, Lieven, Schuurman, Dimitri, Veeckman, Carina   +4 more
core   +1 more source

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Living labs for migrant health research: the challenge of cocreating research with migrant population and policy makers. [PDF]

BMJ Glob Health
Giménez L, Evangelidou S, Gresle AS, de la Torre L, Ubalde-López M, Recasens O, Muñoz E, Pinazo MJ, Requena-Méndez A.   +8 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Editorial: Living labs and open innovation approaches to scale impact for human wellbeing. [PDF]

Front Public Health
Borda A, Schuurman D, Pedell S, Spagnoli F, Konstantinidis E.   +4 more
europepmc   +1 more source